May 7, 2018
LIPIMETIX DEVELOPMENT ANNOUNCES SUB-LICENSE OF APO E MIMETIC PEPTIDE PLATFORM TO ANJI PHARMA, CHINA
Natick, MA – May 7, 2018 ─ LipimetiX Development, Inc. (“LipimetiX” or “the Company”) announced today that Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing agreement for the LipimetiX platform of peptides (AEM-28 and analogs) for development of these drug candidates in commercial indications in mainland China, Taiwan and Hong Kong. Anji Pharma’s mission is to license and develop promising therapeutic technologies that address under-served markets in China.
>> Read More
November 14, 2017
eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
Antithrombotic EP-7041 safe and well tolerated; performed in antithrombotic test range associated with clinical efficacy and with fast onset/offset of activity
>> Read More
December 19, 2016
Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study
Tempe, AZ – December 19, 2016 ─ Capstone Therapeutics Corp. (OTCQB: CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”) announced today that the JV’s lead commercial drug candidate, AEM-28-14, showed substantial and statistically-significant LDL cholesterol (LDLc) reductions in a hypercholesterolemic primate study at Wake Forest University.
>> Read More
Aug. 25, 2016
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc.
TEMPE, Ariz., Aug. 25, 2016 (GLOBE NEWSWIRE) Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”) announced today that the JV’s Series B1 preferred stock offering totaling $1,012,000 closed on August 25, 2016. Individual accredited investors and management participated in the financing.
>> Read More
Feb. 03, 2016
Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period Other OTC_CAPS
TEMPE, Ariz., Feb. 03, 2016 (GLOBE NEWSWIRE) Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today that the Lenders, as defined in the Company’s Current Report on Form 8K filed with the Securities and Exchange Commission dated December 15, 2015, informed the Company that the Lenders would not exercise their option to extend the exclusive due diligence period through March 31, 2016 by loaning Capstone a second $1 million, under the terms of the previouslyreported Securities Purchase
Agreement.
>> Read More
Dec. 15, 2015
Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period Other OTC_CAPS
TEMPE, Ariz., Dec. 15, 2015 (GLOBE NEWSWIRE) Capstone Therapeutics Corp. (OTCQB:CAPS)
(“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today that the Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. ("BVF") have provided a $1 million secured loan to Company as consideration for the Company granting an exclusive period for due diligence, which may lead to an equity investment in Company of up to $10 million.
>> Read More
Oct. 14, 2015
Capstone Therapeutics Announces Allowance of U.S Patent for Treatment of Diabetes with Apo E Mimetic Peptides
TEMPE, Ariz., Oct. 14, 2015 (GLOBE NEWSWIRE) Capstone Therapeutics, Inc. (OTCQB:CAPS) ("the Company") and its (60% owned) joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced today the allowance of U.S. Patent application number 12/675,089 for the use of apolipoprotein E mimetic peptides to decrease plasma glucose in patients with diabetes or insulin resistance.
>> Read More
